Adicet Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Stockholders held by Adicet Bio, Inc. on June 2, 2022. The filing details the voting results for two proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes rather than financial performance.
Material Changes and Voting Results
Two proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Class I Directors
- Aya Jakobovits, Ph.D.: Elected with 20,498,948 votes For, 8,122,158 votes Withheld, and 2,984,290 Broker Non-Votes.
- Chen Schor: Elected with 25,231,131 votes For, 3,389,975 votes Withheld, and 2,984,290 Broker Non-Votes.
- Both directors were elected for a three-year term ending in 2025.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Voting results: 31,592,306 votes For, 10,572 votes Against, and 2,518 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting vote tallies.
Key Facts for Investor Verification
- Confirmation that Aya Jakobovits, Ph.D., and Chen Schor have officially assumed their roles as Class I directors.
- Verification that KPMG LLP is the appointed auditor for the fiscal year ending December 31, 2022.
- Review of the full Proxy Statement filed on April 21, 2022, for detailed biographies of the elected directors and the rationale for the auditor selection.